Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Ratio (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Equity Ratio for 9 consecutive years, with 0.92 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 1.45% to 0.92 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.92 through Dec 2025, up 1.45% year-over-year, with the annual reading at 0.92 for FY2025, 1.45% up from the prior year.
  • Equity Ratio hit 0.92 in Q4 2025 for Protagonist Therapeutics, roughly flat from 0.92 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.94 in Q4 2023 to a low of 0.86 in Q4 2021.
  • Historically, Equity Ratio has averaged 0.89 across 5 years, with a median of 0.89 in 2021.
  • Biggest five-year swings in Equity Ratio: surged 87.29% in 2021 and later fell 4.02% in 2024.
  • Year by year, Equity Ratio stood at 0.86 in 2021, then rose by 0.78% to 0.87 in 2022, then rose by 8.16% to 0.94 in 2023, then dropped by 3.59% to 0.91 in 2024, then rose by 1.45% to 0.92 in 2025.
  • Business Quant data shows Equity Ratio for PTGX at 0.92 in Q4 2025, 0.92 in Q3 2025, and 0.93 in Q2 2025.